A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares.
Parambir S DulaiLaura E RaffalsDavid HudesmanMichael ChioreanRaymond CrossTasneem AhmedMichael WinterShannon ChangDavid FudmanCharlotte SadlerErnest L ChiuFrank L RossGary ToupsM Hassan MuradKinjal SethuramanJames R HolmRenie GuilliodBenjamin LevineJay C BuckeyCorey A SiegelPublished in: Alimentary pharmacology & therapeutics (2020)
Hyperbaric oxygen appears to be effective for optimising response to intravenous steroids in UC patients hospitalised for acute flares, with low rates of re-hospitalisation or colectomy at 3 months. An optimal clinical response is achieved with 5 days of hyperbaric oxygen. Larger phase 3 trials are needed to confirm efficacy and obtain labelled approval.